Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2017 | Pages:
82 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Pipeline Review, H2 2017 Summary According to the recently published report 'Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Pipeline Review, H2 2017'; Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) pipeline Target constitutes close to 25 molecules. Out of which approximately 22 molecules are developed by companies and remaining by the universities/institutes. Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Soluble guanylyl cyclase (sGC) is the known receptor for nitric oxide. Binding of nitric oxide to the heme moiety of the cyclase induces its capacity to synthesize the second messenger cGMP. Although the changes in the state of the heme moiety upon exposure of enzyme to NO and its correlation to the stimulation of sGC catalytic activity. The report 'Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Pipeline Review, H2 2017' outlays comprehensive information on the Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities. It also reviews key players involved in Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 4, 3, 12 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. Report covers products from therapy areas Cardiovascular, Ophthalmology, Metabolic Disorders, Gastrointestinal, Immunology, Oncology, Respiratory, Central Nervous System, Dermatology, Genetic Disorders, Genito Urinary System And Sex Hormones, Hematological Disorders, Infectious Disease and Toxicology which include indications Ocular Hypertension, Glaucoma, Cystic Fibrosis, Resistant Hypertension, Alzheimer's Disease, Chemotherapy Induced Peripheral Neuropathy, Chronic Heart Failure, Chronic Kidney Disease (Chronic Renal Failure), Congestive Heart Failure (Heart Failure), Coronary Artery Disease (CAD) (Ischemic Heart Disease), Diabetic Foot Ulcers, Diabetic Nephropathy, Duchenne Muscular Dystrophy, Esophageal Achalasia, Hypertension, Inflammation, Ischemic Stroke, Liver Diseases, Open-Angle Glaucoma, Optic Neuropathy, Osteoporosis, Pancreatic Cancer, Prostate Cancer, Pulmonary Hypertension, Sickle Cell Disease, Stroke, Systemic Sclerosis (Scleroderma), Tinea pedis (Athlete Foot), Vascular Dementias and Wounds. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - The report reviews Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics and enlists all their major and minor projects - The report assesses Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Overview Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Products under Development by Universities/Institutes Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Companies Involved in Therapeutics Development Bayer AG Boehringer Ingelheim GmbH Ironwood Pharmaceuticals Inc NicOx SA SynZyme Technologies LLC Topadur Pharma AG Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Drug Profiles A-8R - Drug Profile Product Description Mechanism Of Action R&D Progress BAY-1101042 - Drug Profile Product Description Mechanism Of Action R&D Progress BAY-1237592 - Drug Profile Product Description Mechanism Of Action R&D Progress BAY-1636183 - Drug Profile Product Description Mechanism Of Action R&D Progress BI-703704 - Drug Profile Product Description Mechanism Of Action R&D Progress hydroxyurea - Drug Profile Product Description Mechanism Of Action R&D Progress IW-1701 - Drug Profile Product Description Mechanism Of Action R&D Progress IW-1973 - Drug Profile Product Description Mechanism Of Action R&D Progress IW-6463 - Drug Profile Product Description Mechanism Of Action R&D Progress IWP-953 - Drug Profile Product Description Mechanism Of Action R&D Progress naproxcinod - Drug Profile Product Description Mechanism Of Action R&D Progress NCX-1653 - Drug Profile Product Description Mechanism Of Action R&D Progress NCX-429 - Drug Profile Product Description Mechanism Of Action R&D Progress NCX-470 - Drug Profile Product Description Mechanism Of Action R&D Progress NCX-667 - Drug Profile Product Description Mechanism Of Action R&D Progress nitric oxide - Drug Profile Product Description Mechanism Of Action R&D Progress Q-201 - Drug Profile Product Description Mechanism Of Action R&D Progress riociguat - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Activate sGC for Osteoporosis - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Activate Soluble Guanylate Cyclase for Hypertension and Parenchymal Hemorrhage - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Activate Soluble Guanylate Cyclase for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Activate sGC for Liver Diseases - Drug Profile Product Description Mechanism Of Action R&D Progress TOPN-53 - Drug Profile Product Description Mechanism Of Action R&D Progress Vacno - Drug Profile Product Description Mechanism Of Action R&D Progress vericiguat - Drug Profile Product Description Mechanism Of Action R&D Progress Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Dormant Products Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Discontinued Products Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Product Development Milestones Featured News & Press Releases Jun 29, 2017: Bayer Now Enrolling Patients into a Global Pulmonary Arterial Hypertension Study Jun 05, 2017: Novoteris Receives FDA and Health Canada Clearance to Start a Phase 2 Clinical Trial of its Thiolanox Nitric Oxide for the Treatment of Cystic Fibrosis May 19, 2017: Bayer to Present Pulmonary Hypertension Data at the American Thoracic Society 2017 International Conference May 09, 2017: Nicox announces the presentation of scientific data on NCX 667 at ARVO 2017 May 01, 2017: Ironwood Pharmaceuticals to Present New Data for IW-1701 at Digestive Disease Week 2017 Mar 09, 2017: Ironwood Pharmaceuticals provides update on key pipeline program IW-1973 at R&D Day 2017 Feb 21, 2017: Nicox announces the presentation of NCX 667 scientific data at AOPT 2017 Jan 26, 2017: Bayer and Merck to Present Riociguat Data in Rare Pulmonary Diseases at the Annual World Congress of the Pulmonary Vascular Research Institute Jan 24, 2017: Nicox provides clinical and regulatory update for NCX 470 for IOP lowering Oct 18, 2016: Bayer to Present Data in Pulmonary Arterial Hypertension at the 2016 Annual Meeting of the American College of Chest Physicians Sep 28, 2016: Pivotal Phase III Study Started With Vericiguat in Patients With Chronic Heart Failure Sep 16, 2016: Withdrawal of the marketing authorisation application for Adempas (riociguat) Jun 24, 2016: Adempas not for use in patients with pulmonary hypertension caused by idiopathic interstitial pneumonia May 13, 2016: Bayer to Present Pulmonary Hypertension Data at American Thoracic Society 2016 International Conference May 12, 2016: Bayer Terminates Phase II Study with Riociguat in Patients with Pulmonary Hypertension Associated with Idiopathic Interstitial Pneumonias Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables Number of Products under Development by Stage of Development, H2 2017 Number of Products under Development by Therapy Areas, H2 2017 Number of Products under Development by Indications, H2 2017 Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 Number of Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Number of Products under Investigation by Universities/Institutes, H2 2017 Products under Investigation by Universities/Institutes, H2 2017 Number of Products by Stage and Mechanism of Actions, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Pipeline by Bayer AG, H2 2017 Pipeline by Boehringer Ingelheim GmbH, H2 2017 Pipeline by Ironwood Pharmaceuticals Inc, H2 2017 Pipeline by NicOx SA, H2 2017 Pipeline by SynZyme Technologies LLC, H2 2017 Pipeline by Topadur Pharma AG, H2 2017 Dormant Products, H2 2017 Dormant Products, H2 2017 (Contd..1), H2 2017 Dormant Products, H2 2017 (Contd..2), H2 2017 Dormant Products, H2 2017 (Contd..3), H2 2017 Discontinued Products, H2 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
